IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural …
G Zalcman, J Mazieres, A Scherpereel, J Margery… - 2012 - ascopubs.org
TPS7112 Background: MPM median OS does not exceed 13 months with pem/CDDP
doublet. US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab …
doublet. US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab …
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural …
G Zalcman, J Margery, A Scherpereel… - Journal of Clinical …, 2010 - ascopubs.org
7020 Background: MPM median OS does not exceed 13 months with pem/CDDP doublet.
US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an …
US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an …
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS …
G Zalcman, J Mazières, J Margery, L Greillier… - 2015 - ascopubs.org
7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular …
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular …
[HTML][HTML] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
GL Ceresoli, PA Zucali, M Mencoboni, M Botta… - British journal of …, 2013 - nature.com
Background: The aim of this open label phase II study (NCT00407459) was to assess the
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
LM Krug, AJ Wozniak, HL Kindler, R Feld, M Koczywas… - 2012 - ascopubs.org
7029 Background: CBP501, a synthetic duodecapeptide, enhances the cytotoxicity of
cisplatin in cell lines and xenografts, including NCI-H226 human mesothelioma. CBP501 …
cisplatin in cell lines and xenografts, including NCI-H226 human mesothelioma. CBP501 …
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …
G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
[HTML][HTML] Malignant pleural mesothelioma: Some progress, but still a long way from cure
L Lang-Lazdunski - Journal of Thoracic Disease, 2018 - ncbi.nlm.nih.gov
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018; 10 (3): 1172-1177 jtd.
amegroups. com (fluorodeoxyglucose) uptake and total glycolytic value measured by PET …
amegroups. com (fluorodeoxyglucose) uptake and total glycolytic value measured by PET …
Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
T Nakano, K Kuribayashi, M Kondo… - Asia‐Pacific Journal …, 2021 - Wiley Online Library
Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …
A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM).
NM La Verde, A Bramati, M Cinquini… - Journal of Clinical …, 2010 - ascopubs.org
7040 Background: Chemotherapy is the only option for MPM. Cisplatin+ pemetrexed
became the standard in the first-line (FL), while the role of a second-line (SL) remains …
became the standard in the first-line (FL), while the role of a second-line (SL) remains …
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of …
M Pagano, GL Ceresoli, PA Zucali, G Pasello… - 2020 - ascopubs.org
9004 Background. The RAMES Study (EudraCT Number 2016-001132-36) is a multicenter,
double-blind, randomized phase II trial exploring the efficacy and the safety of the addition of …
double-blind, randomized phase II trial exploring the efficacy and the safety of the addition of …